New vaccine trial targets rare skin cancer
NCT ID NCT05799612
First seen Feb 19, 2026 · Last updated May 25, 2026 · Updated 10 times
Summary
This early-stage study was designed to test a personalized mRNA vaccine for people with a rare skin cancer called cutaneous angiosarcoma. The vaccine is made from the patient's own tumor and aims to teach the immune system to fight the cancer. The main goal was to find the highest safe dose and monitor side effects. However, the study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.